| Identification | Back Directory | [Name]
LY2955303 | [CAS]
1433497-19-8 | [Synonyms]
CS-2631
LY2955303
LY2955303 >=98% (HPLC)
LY2955303; LY-2955303; LY 2955303
4-[5-[3,5-Bis(1,1-dimethylethyl)phenyl]-1-[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-1H-pyrazol-3-yl]benzoic acid
Benzoic acid, 4-[5-[3,5-bis(1,1-dimethylethyl)phenyl]-1-[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-1H-pyrazol-3-yl]- | [Molecular Formula]
C36H42N4O3 | [MOL File]
1433497-19-8.mol | [Molecular Weight]
578.74 |
| Chemical Properties | Back Directory | [Boiling point ]
721.9±60.0 °C(Predicted) | [density ]
1.15±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
Chloroform: 25 mg/ml | [form ]
A crystalline solid | [pka]
3.84±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
LY 2955303, is a potent and selective retinoic acid receptor gamma (RARγ) antagonist with a Ki of 1.09 nM. | [Biological Activity]
LY2955303 is a potent and selective RARγ antagonist (Ki = 1.09 nM/RARγ>1.70 μM/RARα>2.98 μM/RARβ) th at effectively inhibits RARγ-but not RARα- or RARβ-dependent reporter activity upon 15 nM all-trans retinoic acid stimulation in respective HEK293 transfectants (KB = 7.11 nM/RARγ1.51 μM/RARβ4.44 μM/RARα; 10 nM ATRA for RARβ transfectant). LY2955303 exhibits therapeutic efficacy in a r at model of osteoarthritis-like joint pain (ED50 = 0.72 mg/kg; single p.o. dosage 9 days post OA pain induction by MIA intra-articular injection) with good pharmacokinetic propertiesaqueous solubility (>1.0 mg/mL in simulated intestinal fluid)oral availability (F = 26%; 10 mg/kg p.o. over 2 mg/kg i.v.)and no RARα antagonism-associated adverse effects (no testicular degeneration up to 10 mg/kg) seen with BMS-189453 treatment or in RARα-knockout mice. | [Synthesis]
1. THF (1790 L) was added to the reactor followed by methyl 4-[5-(3,5-di-tert-butylphenyl)-1-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyrazol-3-yl]benzoate (358 g, 0.605 mol) and water (1140 mL), keeping the temperature at 8-12 °C.
2. lithium hydroxide monohydrate (38 g, 0.905 mol) was added one time and the reaction mixture was stirred at 8-12 °C for 16 hours.
3. After completion of the reaction, EtOAc (30 L) was added and the pH of the mixture was adjusted to 5 with 1N HCl.
4. The two phases were separated and the aqueous layer was extracted with EtOAc (2 x 10 L). The organic layers were combined, dried with sodium sulfate, filtered and the solvent was removed under reduced pressure to give a solid product.
5. The crude product was purified by column chromatography using DCM/MeOH (20/1) as eluent to give a light yellow solid.
6. The solid was ground in a solvent mixture of acetonitrile/MTBE (1/3, 4 L) for 1 h. The solid was collected by filtration.
7. The solid was dried under vacuum at 50 °C for 72 h to give 4-(5-(3,5-di-tert-butylphenyl)-1-(4-(4-methylpiperazine-1-carbonyl)phenyl)-1H-pyrazol-3-yl)benzoic acid (264.2 g, 75% yield) as a white solid. lc-es/ms m/z 579 [M + H]+. | [in vivo]
A single oral dose of LY2955303 demonstrates a dose responsive effect whereby the rat reduces differential weight bearing (ED50=0.72 mg/kg)[1]. | [storage]
Store at -20°C | [References]
[1] Patent: WO2013/66640, 2013, A1. Location in patent: Page/Page column 39
[2] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 14, p. 3274 - 3277 |
|
| Company Name: |
ChemCell Biomedicine Co.,Ltd.
|
| Tel: |
020-13556033878 2965585218 13556033878 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15061/0_EN.htm |
| Company Name: |
Twochem Co.Ltd.
|
| Tel: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
| Company Name: |
Cckinase, Inc.
|
| Tel: |
+1 (732)236-3202 |
| Website: |
www.cckinase.com |
|